Clinical trial information
P-MUC1C-ALLO1 Allogeneic CAR-T for the Treatment of Solid Tumor Cancers
Poseida is currently enrolling patients in a Phase 1 clinical trial for P-MUC1C-ALLO1, an allogeneic off-the-shelf CAR-T treatment in development for a range of epithelial-derived solid tumors, including breast, ovarian, lung, colorectal and other cancers. To find out more about the trial and eligibility, visit clinicaltrials.gov.
P-BCMA-ALLO1 Allogeneic CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma
Poseida is currently enrolling patients in a Phase 1 clinical trial for P-BCMA-ALLO1, an allogeneic off-the-shelf CAR-T treatment in development for patients with relapsed/refractory multiple myeloma. To find out more about the trial and eligibility, visit clinicaltrials.gov.
Expanded access (EA) policy
Expanded access, also known as compassionate use, is a potential pathway for a patient with an immediately life-threatening condition or serious disease to gain access to an investigational drug or other medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. Poseida is committed to developing safe and effective therapies for patients and strives to put patients first. Our goal is to provide a new class of CAR-T and gene therapies to patients as soon as possible through efficient drug development and patient accessibility. Poseida does not currently have any active Expanded Access protocols, nor do we currently provide access to our investigational products on an Expanded Access basis. We encourage patients interested in our investigational products to learn more about our ongoing studies by visiting clinicaltrials.gov.